Physician profile
Warren Foster
NPI 1760666531
$13,092.76
in general payments reported to CMS, 2019-2025
32 companies · $1,124 in 2025
The $1,124 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,506 · 2020: $2,726 · 2021: $487 · 2022: $1,092 · 2023: $2,408 · 2024: $3,751 · 2025: $1,124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $4,761 · Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $4,760.99 |
| Food and Beverage | $2,521.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $3,710.80 | 2019-2025 | Aveir, Ensite, Gallant |
| Medtronic, INC. | $3,559.48 | 2021-2024 | Pulseselect |
| Medtronic Vascular, INC. | $2,920.40 | 2019-2020 | |
| Boston Scientific Corporation | $755.24 | 2019-2025 | Resonate El Icd Vr, Farapulse, Accolade Sr |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $321.84 | 2019-2025 | Lifevest |
| Amgen INC. | $300.32 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $283.54 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $161.47 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $146.77 | 2021-2023 | Verquvo |
| Novartis Pharmaceuticals Corporation | $138.14 | 2022-2024 | |
| Irhythm Technologies, INC. | $125.44 | 2022-2024 | Zio Xt Patch, Zio Monitor |
| Janssen Pharmaceuticals, INC | $107.63 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $86.97 | 2021-2024 | Eliquis, Camzyos |
| Cardiva Medical, INC. | $73.59 | 2022-2025 | Cardiva Vascade Mvp Xl Vvcs 10-12f |
| Boehringer Ingelheim Pharmaceuticals, INC. | $62.43 | 2019-2023 | Jardiance |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $33.80 | 2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $28.54 | 2019-2021 | |
| Philips North America LLC | $28.38 | 2023-2024 | (Cm9) Amb Mon & Diag Und |
| Daiichi Sankyo INC. | $25.26 | 2022 | |
| Esperion Therapeutics, INC. | $24.33 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $21.30 | 2021 | |
| Alnylam Pharmaceuticals INC. | $20.91 | 2025 | Amvuttra |
| Catheter Precision INC. | $20.42 | 2024 | |
| Impulse Dynamics (USA) INC. | $18.02 | 2023 | Optimizer |
| Scpharmaceuticals INC. | $18.00 | 2023 | |
| Novo Nordisk INC | $16.67 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $15.47 | 2019 | |
| Chiesi USA, INC. | $15.46 | 2022 | |
| Bardy Diagnostics, INC. | $15.00 | 2021 | |
| Akcea Therapeutics, INC. | $14.05 | 2019 | |
| Amarin Pharma, INC. | $11.77 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $11.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Warren Foster listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.